1. Home
  2. GRYP vs AIM Comparison

GRYP vs AIM Comparison

Compare GRYP & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRYP
  • AIM
  • Stock Information
  • Founded
  • GRYP 2010
  • AIM 1966
  • Country
  • GRYP United States
  • AIM United States
  • Employees
  • GRYP N/A
  • AIM N/A
  • Industry
  • GRYP
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GRYP
  • AIM Health Care
  • Exchange
  • GRYP Nasdaq
  • AIM Nasdaq
  • Market Cap
  • GRYP 18.0M
  • AIM 15.9M
  • IPO Year
  • GRYP N/A
  • AIM N/A
  • Fundamental
  • Price
  • GRYP $0.38
  • AIM $0.20
  • Analyst Decision
  • GRYP Hold
  • AIM Strong Buy
  • Analyst Count
  • GRYP 1
  • AIM 2
  • Target Price
  • GRYP N/A
  • AIM $2.75
  • AVG Volume (30 Days)
  • GRYP 976.1K
  • AIM 403.8K
  • Earning Date
  • GRYP 11-13-2024
  • AIM 11-15-2024
  • Dividend Yield
  • GRYP N/A
  • AIM N/A
  • EPS Growth
  • GRYP N/A
  • AIM N/A
  • EPS
  • GRYP N/A
  • AIM N/A
  • Revenue
  • GRYP $22,783,000.00
  • AIM $190,000.00
  • Revenue This Year
  • GRYP N/A
  • AIM N/A
  • Revenue Next Year
  • GRYP N/A
  • AIM $1,086.80
  • P/E Ratio
  • GRYP N/A
  • AIM N/A
  • Revenue Growth
  • GRYP 14.06
  • AIM N/A
  • 52 Week Low
  • GRYP $0.38
  • AIM $0.16
  • 52 Week High
  • GRYP $10.30
  • AIM $0.62
  • Technical
  • Relative Strength Index (RSI)
  • GRYP 27.53
  • AIM 40.44
  • Support Level
  • GRYP $0.52
  • AIM $0.20
  • Resistance Level
  • GRYP $0.73
  • AIM $0.23
  • Average True Range (ATR)
  • GRYP 0.08
  • AIM 0.02
  • MACD
  • GRYP -0.03
  • AIM 0.00
  • Stochastic Oscillator
  • GRYP 0.76
  • AIM 10.75

About GRYP Gryphon Digital Mining Inc Common Stock

Gryphon Digital Mining Inc is a Bitcoin mining company. Gryphon's mission is to create the world's leading net carbon-neutral Bitcoin miner. The company will operate a digital asset, mining operation using specialized computers equipped with application-specific integrated circuit (ASIC) chips to solve complex cryptographic algorithms in support of the Bitcoin blockchain in exchange for cryptocurrency rewards (primarily Bitcoin).

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Share on Social Networks: